Axsome 制药

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $251 to $315
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BMO Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $297
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• Truist Financial Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $285
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Jefferies Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $380
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
  TipRanks · 2026/9/22
• Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Jefferies Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $380
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $316
  \u5e02\u573a\u8d44\u8baf · 2026/9/12
• 评级变动
  BMO Capital Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $310
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $297
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $306
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $306
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)
  TipRanks · 2026/7/16
• H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316
  \u5e02\u573a\u8d44\u8baf · 2026/8/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。